Venture Corporation Q3 2026: BUY Rating and S$19.50 Target Price November 18, 2026

Venture Corporation Q3 2026: BUY Rating and S$19.50 Target Price

BRIEF OVERVIEW

Venture Corporation Limited delivered a strong set of 3Q26 results, with 9M26 revenue exceeding expectations at 81% of FY26 estimated forecasts, while profit after tax was within expectations at 73%. Third-quarter earnings jumped 22% year on year to S$67.8 million, with AI-related products — namely networking cards, semiconductors, transceivers and test equipment — driving revenue growth of around 38% year on year. Management guidance pointed to robust demand, with growth across multiple domains and life science beginning to recover. Phillip Securities Research expects FY27 estimated growth to be even stronger, driven by consumer lifestyle products.


INVESTMENT POSITIVES

Strongest Growth in 16 Quarters

Venture’s 3Q26 revenue surged 26% year on year to S$790 million, marking the strongest growth in 16 quarters. Growth was led by Portfolio B products, specifically test and measurement, networking and communications, and semiconductors. This is a noteworthy inflection point for the company, with the breadth and pace of recovery signalling a return to meaningful earnings growth after an extended period of more subdued performance.


AI-Related Products Driving Revenue Momentum

AI-related products were central to the revenue acceleration. Networking cards, semiconductors, transceivers and test equipment collectively drove revenue growth of around 38% year on year in the quarter. Venture is riding on the global data centre build-out with new products, with semiconductor and power equipment identified as key products in this growth cycle. The company’s positioning in these high-growth areas underpins the analyst’s conviction that earnings growth is returning to Venture.


Broad-Based Demand Across Multiple Domains

Management highlighted robust demand across multiple domains, not limited to AI-related segments. The life science domain is beginning to recover, with genomic sequencing equipment identified as a key growth product. The bottoming of life science demand represents an upside surprise for the business, providing an additional avenue for revenue diversification and recovery.


New Products and Capacity Expansion Supporting Outlook

The ramp-up of new products supporting data centre infrastructure, together with new capacity in Malaysia, is driving earnings growth. Additionally, the launch of a new consumer lifestyle product with a narrow supply base is expected to become an added growth driver for FY27 estimated. The analyst expects FY27 estimated growth to be even stronger than FY26, supported by these new product launches and expanded production capacity.


INVESTMENT CHALLENGES

We identified no negatives for Venture Corporation in this quarter. The absence of stated negatives reflects the broad-based strength in demand and the positive trajectory across multiple business domains.


OUTLOOK

Venture Corporation is well positioned to benefit from the ongoing global data centre build-out, with new products across semiconductors and power equipment forming the core of its growth engine. The expected launch of a new consumer lifestyle product with a narrow supply base adds a further growth driver for FY27 estimated. The recovery in life science demand, particularly in genomic sequencing equipment, provides an upside surprise to the earnings outlook. With new manufacturing capacity in Malaysia coming on stream and robust demand across multiple product domains, the analyst sees a constructive outlook for the company in the near to medium term.


RECOMMENDATION AND TARGET PRICE

Phillip Securities Research maintains its BUY recommendation on Venture Corporation with FY26 estimated earnings unchanged. However, the target price has been lowered to S$19.50 from S$22.10. The reduction reflects a lower price-to-earnings multiple of 22 times FY26 estimated earnings, down from 25 times previously, brought in line with US peers. Despite the lower target price, the analyst believes earnings growth is returning to Venture, supported by the ramp-up of new data centre infrastructure products and new capacity in Malaysia.


This article has been auto-generated using PhillipGPT. It is based on a report by a Phillip Securities Research analyst.


Frequently Asked Questions

Q: What is our recommendation and target price for Venture Corporation?

A: Phillip Securities Research maintains a BUY recommendation with a lowered target price of S$19.50, down from S$22.10 previously.

Q: How did Venture Corporation perform in 3Q26?

A: 3Q26 revenue surged 26% year on year to S$790 million, the strongest growth in 16 quarters, while earnings jumped 22% year on year to S$67.8 million.

Q: What drove the strong revenue growth?

A: Growth was led by Portfolio B products, specifically test and measurement, networking and communications, and semiconductors. AI-related products, including networking cards, semiconductors, transceivers and test equipment, drove revenue growth of around 38% year on year.

Q: Why was the target price reduced despite a BUY recommendation being maintained?

A: The price-to-earnings multiple was lowered from 25 times to 22 times FY26 estimated earnings, brought in line with US peers, resulting in the target price reduction from S$22.10 to S$19.50.

Q: Were there any negatives identified by the analyst?

A: No negatives were identified for Venture Corporation in this quarter.

Q: What is the outlook for FY27?

A: We expect FY27 estimated growth to be even stronger than FY26, driven by the launch of a new consumer lifestyle product with a narrow supply base, continued data centre infrastructure demand, and recovery in life science.

Q: How is the life science segment performing?

A: Life science demand is beginning to recover, with genomic sequencing equipment identified as a key growth product. The bottoming of life science demand is considered an upside surprise.

Q: How did 9M26 results compare to full-year estimates?

A: 9M26 revenue exceeded expectations at 81% of FY26 estimated forecasts, while profit after tax was within expectations at 73%.

 

Disclaimer
These commentaries are intended for general circulation and do not have regard to the specific investment objectives, financial situation and particular needs of any person. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. You should seek advice from a financial adviser regarding the suitability of any investment product(s) mentioned herein, taking into account your specific investment objectives, financial situation or particular needs, before making a commitment to invest in such products.

Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of units in any fund and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance.

Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries.

The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries.

Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned.

This advertisement has not been reviewed by the Monetary Authority of Singapore.

IMPORTANT INFORMATION

This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <www.phillipfunds.com> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  

 

Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066 www.phillipfunds.com